Kathleen C Torkko1, R Storey Wilson2, Elizabeth E Smith2, John W Kusek3, Adrie van Bokhoven2, M Scott Lucia2. 1. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic address: kathleen.torkko@ucdenver.edu. 2. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
PURPOSE: Factors associated with worsening of benign prostatic hyperplasia are not well understood. We measured inflammatory markers from prostate biopsies to study if inflammation is related to clinical progression of benign prostatic hyperplasia. MATERIALS AND METHODS: We measured inflammatory cell markers CD45, CD4, CD8 and CD68 in transition zone biopsies from 859 men in the MTOPS biopsy substudy. Using novel imaging techniques we quantified amounts of moderate/severe inflammation. Benign prostatic hyperplasia clinical progression was defined as a confirmed 4-point or greater increase in the AUA symptom score from baseline, or the occurrence of urinary incontinence or acute urinary retention. Baseline clinical parameters including concomitant medication use were determined. Kaplan-Meier curves and multivariate Cox proportional hazard models were used to determine the risk of progression. RESULTS: Inflammation as measured by CD45, CD4 and CD68 increased the risk of clinical progression of benign prostatic hyperplasia. CD4 showed the highest risk where men in the highest tertile of moderate/severe inflammation were at twice the risk of progression compared to men in the lower 2 tertiles combined (HR 2.03, p=0.001). Inflammation was more strongly associated with progression defined by acute urinary retention or incontinence (HR ranging from 2.39 [CD8, p=0.03] to 3.08 [CD4, p=0.01]) than an AUA symptom score increase (CD4, HR 1.86, p=0.01). Men who reported use of nonsteroidal anti-inflammatory drugs or steroids at baseline tended to be at higher risk for progression. CONCLUSIONS: Although our data show that inflammation increases the risk of progression, our findings suggest that inflammation has a greater role in men who have conditions requiring anti-inflammatory medications.
PURPOSE: Factors associated with worsening of benign prostatic hyperplasia are not well understood. We measured inflammatory markers from prostate biopsies to study if inflammation is related to clinical progression of benign prostatic hyperplasia. MATERIALS AND METHODS: We measured inflammatory cell markers CD45, CD4, CD8 and CD68 in transition zone biopsies from 859 men in the MTOPS biopsy substudy. Using novel imaging techniques we quantified amounts of moderate/severe inflammation. Benign prostatic hyperplasia clinical progression was defined as a confirmed 4-point or greater increase in the AUA symptom score from baseline, or the occurrence of urinary incontinence or acute urinary retention. Baseline clinical parameters including concomitant medication use were determined. Kaplan-Meier curves and multivariate Cox proportional hazard models were used to determine the risk of progression. RESULTS:Inflammation as measured by CD45, CD4 and CD68 increased the risk of clinical progression of benign prostatic hyperplasia. CD4 showed the highest risk where men in the highest tertile of moderate/severe inflammation were at twice the risk of progression compared to men in the lower 2 tertiles combined (HR 2.03, p=0.001). Inflammation was more strongly associated with progression defined by acute urinary retention or incontinence (HR ranging from 2.39 [CD8, p=0.03] to 3.08 [CD4, p=0.01]) than an AUA symptom score increase (CD4, HR 1.86, p=0.01). Men who reported use of nonsteroidal anti-inflammatory drugs or steroids at baseline tended to be at higher risk for progression. CONCLUSIONS: Although our data show that inflammation increases the risk of progression, our findings suggest that inflammation has a greater role in men who have conditions requiring anti-inflammatory medications.
Authors: Laura E Pascal; Rajiv Dhir; Goundappa K Balasubramani; Wei Chen; Chandler N Hudson; Pooja Srivastava; Anthony Green; Donald B DeFranco; Naoki Yoshimura; Zhou Wang Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Ibrahim Kulac; Berrak Gumuskaya; Charles G Drake; Beverly Gonzalez; Kathryn B Arnold; Phyllis J Goodman; Alan R Kristal; M Scott Lucia; Ian M Thompson; William B Isaacs; Angelo M De Marzo; Elizabeth A Platz Journal: Prostate Date: 2016-06-21 Impact factor: 4.104
Authors: William A Ricke; Calvin W Lee; Tyler R Clapper; Andrew J Schneider; Robert W Moore; Kimberly P Keil; Lisa L Abler; Jalissa L Wynder; Arnaldo López Alvarado; Isaac Beaubrun; Jenny Vo; Tyler M Bauman; Emily A Ricke; Richard E Peterson; Chad M Vezina Journal: Toxicol Sci Date: 2016-02-09 Impact factor: 4.849
Authors: Ling Hao; Yatao Shi; Samuel Thomas; Chad M Vezina; Sagar Bajpai; Arya Ashok; Charles J Bieberich; William A Ricke; Lingjun Li Journal: Int J Mass Spectrom Date: 2018-09-22 Impact factor: 1.986